VLVladimir Ljubicic

Vladimir Ljubicic

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Vladimir Ljubicic has a total of 100 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Arginine methyltransferase signalling is hyperactive in conditions of neuromuscular junction instability and muscle atrophy

    by Andrew I Mikhail, Sean Y Ng, Magda A Lesinski, Stephanie R Mattina, Derek W Stouth, Rozhin Raziee, Changhyun Lim, Gautham Vasam, Keir J Menzies, Stuart M Phillips, et al.

    Background: The neuromuscular junction (NMJ) is the site of communication between myofibers and a-motor neurons. Cellular and molecular mechanisms that determine, maintain, and remodel the neuromuscular synapse are poorly understood. Coactivator-associated arginine methyltransferase 1 (CARM1) post-translationally modifies target proteins by methylating arginine residues and has emerged as a key determinant of skeletal muscle biology. Methylarginine signalling is required for the maintenance and repair of the NMJ, but the direct role of CARM1 on the NMJ in health and disease remains unexplored, particularly in humans. Methods: We generated Carm1 skeletal muscle-specific knockout-out (mKO) mice to gain a basic understanding for the role of the enzyme in NMJ biology under homeostatic and denervated conditions. Additionally, we investigated CARM1 activity in severe mouse models of neuromuscular disorders (NMDs) including D2.mdx and Smn2B/- mice, which replicate Duchenne's muscular dystrophy (DMD) and spinal muscular atrophy (SMA), respectively, and exhibit chronic remodelling of the NMJ. Lastly, to evaluate if methylarginine signalling is implicated during NMJ instability in human skeletal muscle, we obtained samples from healthy volunteers before and after 14 days of single leg immobilization as well as from patients with myotonic dystrophy type 1. Results: Our results demonstrated that Carm1 mRNA expression and activity are elevated (P<0.05) in NMJ-enriched regions of healthy murine skeletal muscle. Carm1 muscle-specific deletion reduced NMJ compactness (-9.3%; P<0.05), increased fragmentation (+33%; P<0.05), and disrupted the expression of synapse-specific transcripts basally and following sciatic nerve transection. In skeletal muscle from pre-clinical models of NMDs, we observed a compensatory upregulation in CARM1-dependent arginine methylation as evident by +54% and +71 increases (P<0.05) in asymmetric dimethylarginine (ADMA)-marked CARM1 substrates in DMD and SMA mice, respectively. Similarly, muscle CARM1 was hyperactive with increased NMJ instability during neuromuscular disuse (+22%; P<0.05), and disease (+30%; P<0.05), in humans. In a cohort of muscular dystrophy patients and healthy volunteers, elevated CARM1 signalling was negatively correlated with clinical metrics of skeletal muscle health including grip strength (r = -0.583; P<0.05) as well as positively correlated with mRNA expression of NMJ machinery such as CHRNA1 (r = 0.578; P<0.05). Conclusion: In summary, we highlight that muscle-specific CARM1 is required for maintaining NMJ morphology and transcriptional regulation. Insults to NMJ stability during muscle disuse or in myopathic conditions were associated with enhanced CARM1-mediated methylarginine signalling in mice and humans. Collectively, our findings demonstrate CARM1 as a key mediator of NMJ biology and plasticity in health and disease.

  • Open Access

    Direct AMPK Activation Confers Mutation‐Independent Therapeutic Benefit in Duchenne Muscular Dystrophy

    by Sean Y. Ng, Andrew I. Mikhail, Stephanie R. Mattina, Magda A. Lesinski, Irena A. Rebalka, Sophie I. Hamstra, Donald Xhuti, Val A. Fajardo, Mark A. Tarnopolsky, Joshua P. Nederveen, et al.

    Background: Duchenne muscular dystrophy (DMD) is a severe, life‐limiting neuromuscular disorder (NMD) characterized by progressive muscle wasting and mitochondrial dysfunction. Although gene therapies offer promise, even those already approved by regulatory agencies, their use remains constrained by mutation specificity, delivery challenges and durability. Pharmacologically targeting AMPK has shown potential to ameliorate dystrophic pathology, but prior strategies have been hindered by inadequate efficacy and off‐target effects. Methods: Comparative transcriptomic analyses were conducted to assess concordance between gene expression profiles induced by direct AMPK activation and those observed in DMD patient muscle. To evaluate the therapeutic potential of sustained AMPK activation, DBA/2J‐mdx (D2.mdx; n = 8–10) mice were treated daily with MK‐8722 (MK; 5 mg·kg −1 ) or vehicle for 7 weeks, with healthy DBA/2J mice serving as controls. Additionally, DMD patient‐derived myotubes ( n = 4) were treated with MK (1 μM, 24 h) to assess AMPK‐mediated cellular adaptations in human cells. Results: Transcriptomic profiling revealed that MK modulated 206 DMD‐associated transcripts, reversing expression of 73 upregulated and 133 downregulated genes. In vivo, MK‐treated D2.mdx mice showed enhanced AMPK signalling (ACC phosphorylation, +120%–150%; p < 0.05), increased Ppargc1a expression (+60%, p < 0.05) and reduced inflammation‐ and fibrosis‐associated transcripts (−25%–50%; p < 0.05). Seven weeks of daily MK treatment enhanced (+95%; p < 0.05) whole‐body lipid oxidation during active periods without affecting energy expenditure or activity. Notably, we observed that repeated MK dosing did not adversely impact cardiac morphology or function ( p > 0.05). MK‐treated D2.mdx mice demonstrated improved grip strength fatigability (−35%, p < 0.05), inverted hang performance (+100%, p < 0.05) and treadmill exercise capacity (+20%, p < 0.05). Additional ex vivo muscle assessments revealed (+30%; p < 0.05) greater peak isometric force and improved twitch contractile kinetics. These functional adaptations were coincident with reduced myofibre damage and fibrosis, with increased sarcolemmal expression of utrophin, γ‐sarcoglycan and β‐dystroglycan (+10%–70%; p < 0.05), despite no changes in fibre size or mass. Mitochondrial assessments showed increased State III respiration (+80%; p < 0.05), reduced reactive oxygen species production (−70%; p < 0.05) and elevated OXPHOS protein content (+25%–45%; p < 0.05). In patient‐derived myotubes, MK similarly activated AMPK signalling, increased mitochondrial electron transport chain proteins (+25%–35%; p < 0.05) and enhanced maximal oxygen consumption (+50%–80%; p < 0.05) in DMDΔ44 and DMDΔ45 lines. Conclusions: These findings demonstrate that sustained, systemic activation of AMPK safely improves muscle function, metabolic health and dystrophic pathology in a mutation‐independent manner. This supports the therapeutic potential of direct AMPK agonists as a disease‐modifying strategy for DMD and other neuromuscular disorders.


  • Open Access

    Volitional exercise elicits physiological and molecular improvements in the severe D2.mdx mouse model of Duchenne muscular dystrophy

    by Stephanie R. Mattina, Sean Y. Ng, Andrew I. Mikhail, Derek W. Stouth, Cora E. Jornacion, Irena A. Rebalka, Thomas J. Hawke, Vladimir Ljubicic

    Duchenne muscular dystrophy (DMD) is characterized by progressive muscle wasting and weakness. Prescribed moderate exercise in patients is beneficial, but concerns remain due to the vulnerability of dystrophic muscle to damage. Voluntary wheel running (VWR) is a self‐regulated form of exercise that improves muscle health in the typical C57.mdx mouse model of DMD. The purpose of the current study was to investigate the impact of VWR in more severe and clinically relevant D2.mdx mice. Male D2.mdx animals were assigned to a sedentary (D2.mdx SED) or VWR group for 8–10 weeks, whereas DBA/2J wild‐type mice served as healthy, sedentary controls (WT SED). Selective skeletal muscle mass and ex vivo force generation were elevated in D2.mdx animals that ran a relatively high volume (D2.mdx High VWR; 1.84 ± 0.84 km/day) compared to low‐volume runners (D2.mdx Low VWR; 0.46 ± 0.31 km/day) and SED counterparts. VWR did not exacerbate the dystrophy, and instead attenuated the fibrotic profile compared to D2.mdx SED mice. A VWR‐induced shift towards a more slow, oxidative phenotype was also observed. Mitochondrial respiration was reduced in D2.mdx SED animals versus WT SED mice but was partially restored following both Low and High VWR. Finally, a dose‐dependent increase in the expression of mitochondrial proteins was observed following VWR, whereas markers of mitochondrial fusion were particularly elevated in D2.mdx High VWR mice. Our results indicate that VWR enhances muscle and mitochondrial biology in D2.mdx animals and further supports the therapeutic role of exercise for DMD patients. image Key points: Duchenne muscular dystrophy (DMD) is a life‐limiting neuromuscular disorder characterized by muscle weakness and wasting. Skeletal and cardiac muscle quality is compromised in the dystrophic condition. Exercise promotes functional and molecular adaptations in healthy individuals and mild dystrophic mouse models. However, the effects of exercise in more severe and clinically relevant models of DMD require investigation. A relatively high volume of voluntary wheel running (VWR) augmented selective muscle mass and muscle function without exacerbating the dystrophic pathology in D2.mdx mice. Volitional exercise normalized dystrophic skeletal muscle mitochondrial respiration and upregulated mitochondrial content compared to sedentary counterparts. A higher dose of VWR increased organelle fusion protein expression compared to both healthy and dystrophic sedentary animals, as well as D2.mdx mice that ran lower volumes. Our results provide evidence from a severe preclinical model that volitional exercise may be a safe and efficacious lifestyle‐based intervention for DMD.


  • Open Access

    Skeletal Muscle Mitochondrial and Autophagic Dysregulation Are Modifiable in Spinal Muscular Atrophy

    by Andrew I. Mikhail, Sean Y. Ng, Donald Xhuti, Magda A. Lesinski, Jennifer Chhor, Marc‐Olivier Deguise, Yves De Repentigny, Joshua P. Nederveen, Rashmi Kothary, Mark A. Tarnopolsky, et al.

    Background: Spinal muscular atrophy (SMA) is a health‐ and life‐limiting neuromuscular disorder. Although varying degrees of mitochondrial abnormalities have been documented in SMA skeletal muscle, the influence of disease progression on pathways that govern organelle turnover and dynamics are poorly understood. Thus, the purpose of this study was to investigate skeletal muscle mitochondria during SMA disease progression and determine the effects of therapeutic modalities on organelle biology. Methods: Smn 2B/+ and Smn 2B/− severe SMA‐like mice were used to investigate mitochondrial turnover and dynamics signalling. Muscles were analysed at postnatal day 9 (P9), P13 or P21 to address pre‐symptomatic, early symptomatic and late symptomatic periods of the disorder. Additionally, we utilized an acute dose of exercise and urolithin A (UA) to stimulate organelle remodelling in skeletal muscle of SMA mice in vivo and in SMA patient‐derived myotubes in vitro, respectively. Results: Smn 2B/+ and Smn 2B/− mice demonstrated similar levels of muscle mitochondrial oxidative phosphorylation (OxPhos) proteins throughout disease progression. In contrast, at P21 the mRNA levels of upstream factors important for the transcription of mitochondrial genes encoded by the nuclear and mitochondrial DNA, including nuclear respiratory factor 2 , sirtuin 1 , mitochondrial transcription factor A and tumour protein 53 , were upregulated (+31%–195%, p < 0.05) in Smn 2B/− mice relative to Smn 2B/+ . Early and late symptomatic skeletal muscle from SMA‐like mice showed greater autophagosome formation as denoted by more phosphorylated autophagy related 16‐like 1 (p‐ATG16L1 Ser278 ) puncta (+60%–80%, p < 0.05), along with a build‐up of molecules indicative of damaged mitochondria such as BCL2 interacting protein 3, Parkin and PTEN‐induced kinase 1 (+100%–195%, p < 0.05). Furthermore, we observed a fragmented mitochondrial phenotype at P21 that was concomitant with abnormal splicing of Optic atrophy 1 transcripts (−53%, p < 0.05). A single dose of exercise augmented the expression of citrate synthase (+43%, p < 0.05) and corrected the over‐assembly of autophagosomes (−64%, p < 0.05). In patient muscle cells, UA treatment stimulated autophagic flux, increased the expression of OxPhos proteins (+15%–47%, p < 0.05) and improved maximal oxygen consumption (+84%, p < 0.05). Conclusions: Abnormal skeletal muscle mitochondrial turnover and dynamics are associated with disease progression in Smn 2B/− mice despite compensatory elevations in upstream factors important for organelle synthesis and recycling. Exercise and UA enhance mitochondrial health in skeletal muscle, which indicates that lifestyle‐based and pharmacological interventions may be effective countermeasures targeting the organelle for therapeutic remodelling in SMA.


  • Open Access

    AMPK regulates the maintenance and remodelling of the neuromuscular junction

    by Sean Y. Ng, Andrew I. Mikhail, Stephanie R. Mattina, Salah A. Mohammed, Shahzeb K. Khan, Eric M. Desjardins, Changhyun Lim, Stuart M. Phillips, Gregory R. Steinberg, Vladimir Ljubicic


  • Open Access

    CARM1 drives mitophagy and autophagy flux during fasting-induced skeletal muscle atrophy

    by Derek W. Stouth, Tiffany L. Vanlieshout, Andrew I. Mikhail, Sean Y. Ng, Rozhin Raziee, Brittany A. Edgett, Goutham Vasam, Erin K. Webb, Kevin S. Gilotra, Matthew Markou, et al.

    CARM1 (coactivator associated arginine methyltransferase 1) has recently emerged as a powerful regulator of skeletal muscle biology. However, the molecular mechanisms by which the methyltransferase remodels muscle remain to be fully understood. In this study, carm1 skeletal muscle-specific knockout (mKO) mice exhibited lower muscle mass with dysregulated macroautophagic/autophagic and atrophic signaling, including depressed AMP-activated protein kinase (AMPK) site-specific phosphorylation of ULK1 (unc-51 like autophagy activating kinase 1; Ser555) and FOXO3 (forkhead box O3; Ser588), as well as MTOR (mechanistic target of rapamycin kinase)-induced inhibition of ULK1 (Ser757), along with AKT/protein kinase B site-specific suppression of FOXO1 (Ser256) and FOXO3 (Ser253). In addition to lower mitophagy and autophagy flux in skeletal muscle, carm1 mKO led to increased mitochondrial PRKN/parkin accumulation, which suggests that CARM1 is required for basal mitochondrial turnover and autophagic clearance. carm1 deletion also elicited PPARGC1A (PPARG coactivator 1 alpha) activity and a slower, more oxidative muscle phenotype. As such, these carm1 mKO-evoked adaptations disrupted mitophagy and autophagy induction during food deprivation and collectively served to mitigate fasting-induced muscle atrophy. Furthermore, at the threshold of muscle atrophy during food deprivation experiments in humans, skeletal muscle CARM1 activity decreased similarly to our observations in mice, and was accompanied by site-specific activation of ULK1 (Ser757), highlighting the translational impact of the methyltransferase in human skeletal muscle. Taken together, our results indicate that CARM1 governs mitophagic, autophagic, and atrophic processes fundamental to the maintenance and remodeling of muscle mass. Targeting the enzyme may provide new therapeutic approaches for mitigating skeletal muscle atrophy.


  • Open Access

    Sex-Specific Effect of CARM1 in Skeletal Muscle Adaptations to Exercise

    by Tiffany L. Vanlieshout, Derek W. Stouth, Rozhin Raziee, Anne-Sophie J. Sraka, Hooriya A. Masood, Sean Y. Ng, Stephanie R. Mattina, Andrew I. Mikhail, Alexander Manta, Vladimir Ljubicic

    Purpose: The purpose of this study was to determine how the intersection of coactivator-associated arginine methyltransferase 1 (CARM1) and biological sex affects skeletal muscle adaptations to chronic physical activity. Methods: Twelve-week-old female (F) and male (M) wild-type (WT) and CARM1 skeletal muscle-specific knockout (mKO) mice were randomly assigned to sedentary (SED) or voluntary wheel running (VWR) experimental groups. For 8 wk, the animals in the VWR cohort had volitional access to running wheels. Subsequently, we performed whole-body functional tests, and 48 h later muscles were harvested for molecular analysis. Western blotting, enzyme activity assays, as well as confocal and transmission electron microscopy were used to examine skeletal muscle biology. Results: Our data reveal a sex-dependent reduction in VWR volume caused by muscle-specific ablation of CARM1, as F CARM1 mKO mice performed less chronic, volitional exercise than their WT counterparts. Regardless of VWR output, exercise-induced adaptations in physiological function were similar between experimental groups. A broad panel of protein arginine methyltransferase (PRMT) biology measurements, including markers of arginine methyltransferase expression and activity, were unaffected by VWR, except for CARM1 and PRMT7 protein levels, which decreased and increased with VWR, respectively. Changes in myofiber morphology and mitochondrial protein content showed similar trends among animals. However, a closer examination of transmission electron microscopy images revealed contrasting responses to VWR in CARM1 mKO mice compared with WT littermates, particularly in mitochondrial size and fractional area. Conclusions: The present findings demonstrate that CARM1 mKO reduces daily running volume in F mice, as well as exercise-evoked skeletal muscle mitochondrial plasticity, which indicates that this enzyme plays an essential role in sex-dependent differences in exercise performance and mitochondrial health.


  • Open Access

    Impact of short-term, pharmacological CARM1 inhibition on skeletal muscle mass, function, and atrophy in mice

    by Erin K. Webb, Sean Y. Ng, Andrew I. Mikhail, Derek W. Stouth, Tiffany L. Vanlieshout, Anika L. Syroid, Vladimir Ljubicic

    Short-term pharmacological inhibition of coactivator-associated arginine methyltransferase 1 (CARM1) was effective at significantly reducing CARM1 methyltransferase function in skeletal muscle. CARM1 inhibition did not impact muscle mass, but exercise capacity was impaired, particularly in male mice, whereas morphological and molecular signatures of denervation-induced muscle atrophy were largely maintained in animals administered the inhibitor. Altogether, the role of CARM1 in neuromuscular biology remains complex and requires further investigation of its therapeutic potential in muscle-wasting conditions.


  • Open Access

    AMPK is mitochondrial medicine for neuromuscular disorders

    by Andrew I. Mikhail, Sean Y. Ng, Stephanie R. Mattina, Vladimir Ljubicic


  • Open Access

    Acute, next‐generation AMPK activation initiates a disease‐resistant gene expression program in dystrophic skeletal muscle

    by Sean Y. Ng, Andrew I. Mikhail, Stephanie R. Mattina, Alexander Manta, Ian J. Diffey, Vladimir Ljubicic

    Duchenne muscular dystrophy (DMD) is a life‐limiting neuromuscular disorder characterized by muscle weakness and wasting. Previous proof‐of‐concept studies demonstrate that the dystrophic phenotype can be mitigated with the pharmacological stimulation of AMP‐activated protein kinase (AMPK). However, first‐generation AMPK activators have failed to translate from bench to bedside due to either their lack of potency or toxic, off‐target effects. The identification of safe and efficacious molecules that stimulate AMPK in dystrophic muscle is of particular importance as it may broaden the therapeutic landscape for DMD patients regardless of their specific dystrophin mutation. Here, we demonstrate that a single dose of the next generation, orally‐bioactive AMPK agonist MK‐8722 (MK) to mdx mice evoked skeletal muscle AMPK and extensive downstream stimulation within 12 h post‐treatment. Specifically, MK elicited a gene expression profile indicative of a more disease‐resistant slow, oxidative phenotype including increased peroxisome proliferator‐activated receptor ɣ coactivator‐1⍺ activity and utrophin levels. In addition, we observed augmented autophagy signaling downstream of AMPK, as well as elevations in critical autophagic genes such as Map1lc3 and Sqstm1 subsequent to the myonuclear accumulation of the master regulator of the autophagy gene program, transcription factor EB. Lastly, we show that pharmacological AMPK stimulation normalizes the expression of myogenic regulatory factors and amends activated muscle stem cell content in mdx muscle. Our results indicate that AMPK activation via MK enhances disease‐mitigating mechanisms in dystrophic muscle and prefaces further investigation on the chronic effects of novel small molecule AMPK agonists.